CO2023013001A2 - Uso de un agonista del receptor de orexina 2 para la recuperación posoperatoria - Google Patents
Uso de un agonista del receptor de orexina 2 para la recuperación posoperatoriaInfo
- Publication number
- CO2023013001A2 CO2023013001A2 CONC2023/0013001A CO2023013001A CO2023013001A2 CO 2023013001 A2 CO2023013001 A2 CO 2023013001A2 CO 2023013001 A CO2023013001 A CO 2023013001A CO 2023013001 A2 CO2023013001 A2 CO 2023013001A2
- Authority
- CO
- Colombia
- Prior art keywords
- orexin
- postoperative recovery
- receptor agonist
- subject
- methyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163170211P | 2021-04-02 | 2021-04-02 | |
| PCT/IB2022/053085 WO2022208478A1 (en) | 2021-04-02 | 2022-04-01 | Use of an orexin 2 receptor agonist for post operation recovery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023013001A2 true CO2023013001A2 (es) | 2023-10-30 |
Family
ID=81326367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0013001A CO2023013001A2 (es) | 2021-04-02 | 2023-09-29 | Uso de un agonista del receptor de orexina 2 para la recuperación posoperatoria |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240165092A1 (https=) |
| EP (1) | EP4313045A1 (https=) |
| JP (1) | JP2024511676A (https=) |
| KR (1) | KR20230165782A (https=) |
| CN (1) | CN117396203A (https=) |
| AU (1) | AU2022252108A1 (https=) |
| BR (1) | BR112023020104A2 (https=) |
| CA (1) | CA3215906A1 (https=) |
| CO (1) | CO2023013001A2 (https=) |
| MX (1) | MX2023011669A (https=) |
| TW (1) | TW202304437A (https=) |
| WO (1) | WO2022208478A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202502342A (zh) * | 2023-06-02 | 2025-01-16 | 日商武田藥品工業股份有限公司 | 食慾素２受體促效劑用於改善睡眠期間之呼吸功能的用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5854204A (en) | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals, Inc. | Aβ peptides that modulate β-amyloid aggregation |
| JP2001500852A (ja) | 1996-08-27 | 2001-01-23 | プレーシス ファーマスーティカルズ インコーポレイテッド | Ｄ―アミノ酸を含むβ―アミロイドペプチド凝集のモジュレーター |
| PL3411358T3 (pl) * | 2016-02-04 | 2022-02-28 | Takeda Pharmaceutical Company Limited | Podstawiony związek piperydynowy i jego zastosowanie |
| US11034700B2 (en) | 2017-03-08 | 2021-06-15 | Takeda Pharmaceutical Company Limited | Substituted pyrrolidine compound and use thereof |
| WO2018164191A1 (ja) | 2017-03-08 | 2018-09-13 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
| US11319286B2 (en) | 2017-08-03 | 2022-05-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| US20200207734A1 (en) | 2017-08-03 | 2020-07-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| US12077522B2 (en) | 2018-06-29 | 2024-09-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| JP7413261B2 (ja) | 2018-06-29 | 2024-01-15 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| EP3896060B1 (en) | 2018-12-12 | 2023-08-16 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JP7379374B2 (ja) | 2018-12-12 | 2023-11-14 | 武田薬品工業株式会社 | 複素環化合物 |
| SG11202106791XA (en) | 2019-01-31 | 2021-07-29 | Takeda Pharmaceuticals Co | Heterocyclic compound and use thereof |
| US11098029B2 (en) | 2019-02-13 | 2021-08-24 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
| WO2020167701A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | Pyrrolidine orexin receptor agonists |
| WO2021026047A1 (en) | 2019-08-08 | 2021-02-11 | Merck Sharp & Dohme Corp. | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
| CA3154321A1 (en) * | 2019-09-13 | 2021-03-18 | Takeda Pharmaceutical Company Limited | Tak-925 for use in treating narcolepsy |
-
2022
- 2022-04-01 BR BR112023020104A patent/BR112023020104A2/pt unknown
- 2022-04-01 CN CN202280037124.XA patent/CN117396203A/zh active Pending
- 2022-04-01 US US18/553,348 patent/US20240165092A1/en active Pending
- 2022-04-01 CA CA3215906A patent/CA3215906A1/en active Pending
- 2022-04-01 TW TW111112864A patent/TW202304437A/zh unknown
- 2022-04-01 AU AU2022252108A patent/AU2022252108A1/en active Pending
- 2022-04-01 WO PCT/IB2022/053085 patent/WO2022208478A1/en not_active Ceased
- 2022-04-01 EP EP22715747.6A patent/EP4313045A1/en active Pending
- 2022-04-01 KR KR1020237033928A patent/KR20230165782A/ko active Pending
- 2022-04-01 MX MX2023011669A patent/MX2023011669A/es unknown
- 2022-04-01 JP JP2023560767A patent/JP2024511676A/ja active Pending
-
2023
- 2023-09-29 CO CONC2023/0013001A patent/CO2023013001A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022208478A1 (en) | 2022-10-06 |
| KR20230165782A (ko) | 2023-12-05 |
| CN117396203A (zh) | 2024-01-12 |
| US20240165092A1 (en) | 2024-05-23 |
| CA3215906A1 (en) | 2022-10-06 |
| JP2024511676A (ja) | 2024-03-14 |
| AU2022252108A1 (en) | 2023-10-05 |
| BR112023020104A2 (pt) | 2023-11-14 |
| MX2023011669A (es) | 2023-10-18 |
| TW202304437A (zh) | 2023-02-01 |
| EP4313045A1 (en) | 2024-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022004596A2 (es) | Tak-925 para uso en el tratamiento de la narcolepsia | |
| CO2022004589A2 (es) | Uso de un agonista del receptor de orexina 2 para el tratamiento de la somnolencia excesiva | |
| MX2025015186A (es) | Inhibidores de pi3k y uso de estos | |
| ES2539430T3 (es) | Derivados de metastina y uso de los mismos | |
| MX2021013854A (es) | Compuestos para tratar enfermedad de huntington. | |
| BRPI0417684A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| CL2010000188A1 (es) | Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso. | |
| GT200600359A (es) | Fungicidal n-[2-(haloalkoxy)phenyl]heteroarylcarboxamides | |
| ES2531190T3 (es) | Método para producir un compuesto de 4-oxoquinolina | |
| PE20080999A1 (es) | Azolilmetiloxiranos, su uso para combatir hongos fitopatogenos, asi como productos que los contienen | |
| CO2023013001A2 (es) | Uso de un agonista del receptor de orexina 2 para la recuperación posoperatoria | |
| BR112015026847A2 (pt) | tiazóis e usos dos mesmos | |
| AR049578A1 (es) | Derivados de hidantoina, procesos de obtencion y composiciones farmaceuticas | |
| ATE145897T1 (de) | Carbocyclische sulfonamide als agoniste oder antagoniste von pgez | |
| MX2020011339A (es) | Polímero catiónico y uso para suministro de biomolecúla. | |
| BR112022013547A2 (pt) | Métodos para potencializar a farmacocinética, para aumentar a concentração plasmática e a vigília ou diminuir a sonolência excessiva, e, composição | |
| AR124694A1 (es) | Hidrato cristalino de sal de sodio de topramezona novedoso y método de preparación del mismo | |
| MX2022012575A (es) | Compuestos para usarse para tratar la enfermedad de huntington. | |
| CO2023018652A2 (es) | Compuestos de triptamina fluorada, análogos de estos y métodos de uso de estos | |
| CL2022001353A1 (es) | Inhibidores de egfr | |
| EP4364811A3 (en) | Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin | |
| PE20080949A1 (es) | Azolilmetiloxiranos, su uso para combatir hongos fitopatogenos, asi como productos que los contienen | |
| AR049681A1 (es) | Macrolidos preparados a partir de actinomicetos. composiciones farmaceuticas | |
| BR112022002269A2 (pt) | Composição farmacêutica, e, método para preparar a composição farmacêutica | |
| ECSP21003130A (es) | Compuestos de isoxazolina para controlar plagas de invertebrados |